78.93
前日終値:
$74.42
開ける:
$76
24時間の取引高:
934.87K
Relative Volume:
1.22
時価総額:
$6.44B
収益:
$39.21M
当期純損益:
$-311.35M
株価収益率:
-21.45
EPS:
-3.6793
ネットキャッシュフロー:
$-234.34M
1週間 パフォーマンス:
-0.27%
1か月 パフォーマンス:
-12.96%
6か月 パフォーマンス:
+46.89%
1年 パフォーマンス:
+148.05%
Kymera Therapeutics Inc Stock (KYMR) Company Profile
名前
Kymera Therapeutics Inc
セクター
電話
857-285-5314
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc
|
78.93 | 6.08B | 39.21M | -311.35M | -234.34M | -3.6793 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
|
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 再開されました | Jefferies | Buy |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-06 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | 再開されました | Guggenheim | Buy |
| 2025-10-24 | 繰り返されました | B. Riley Securities | Buy |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-16 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-07-30 | 再開されました | B. Riley Securities | Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-06-03 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-05-20 | 再開されました | Stifel | Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-12-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-26 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 開始されました | Oppenheimer | Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 開始されました | Truist | Buy |
| 2023-05-05 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 開始されました | Raymond James | Mkt Perform |
| 2022-08-15 | 開始されました | Jefferies | Buy |
| 2022-08-03 | 開始されました | Goldman | Buy |
| 2022-07-20 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | JP Morgan | Neutral |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2021-09-30 | 開始されました | B. Riley Securities | Neutral |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-09-15 | 開始されました | BofA Securities | Neutral |
| 2020-09-15 | 開始されました | Cowen | Outperform |
| 2020-09-15 | 開始されました | Guggenheim | Buy |
| 2020-09-15 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Kymera Therapeutics Inc (KYMR) 最新ニュース
Kymera Therapeutics (NASDAQ:KYMR) COO Sells $7,063,662.50 in Stock - MarketBeat
Jeremy Chadwick Sells 24,727 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Shares Up 8.4%What's Next? - MarketBeat
Kymera Therapeutics (KYMR) to present Phase 1b BroADen trial data for KT-621 at AAD 2026 - MSN
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
A Look At Kymera Therapeutics (KYMR) Valuation After Late Breaking KT-621 AAD 2026 Selection - Sahm
Kymera’s KT-621 Faces "Sell the News" Risk as AAD Data and Dilution Collide - Bitget
Jobs Data: Can Kymera Therapeutics Inc benefit from deglobalization2026 Retail & Safe Entry Point Identification - baoquankhu1.vn
Kymera Q4 loss wider than expected, cash boost extends runway - MSN
Esposito sells Kymera (KYMR) shares worth $197,877 By Investing.com - Investing.com Canada
Kymera Therapeutics (KYMR) director exercises options, sells 2,500 shares under 10b5-1 plan - Stock Titan
Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026 - Insider Monkey
Stock Recap: Is Kymera Therapeutics Inc currently under institutional pressure2026 Closing Moves & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Highs Report: Is now the right time to enter Kymera Therapeutics IncMarket Performance Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
(KYMR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Nextech Invest Sells $4.19M in Kymera Shares, Stake Value Rises to $21.7MNews and Statistics - IndexBox
Nextech Trims Kymera at a Recent High — think Foolishly before acting. - Yahoo Finance
15 Most Promising Stocks Under $100 to Buy - Insider Monkey
Aug Selloffs: What is the long term forecast for Kymera Therapeutics Inc stock2026 Market Sentiment & Pattern Based Trade Signal System - baoquankhu1.vn
Aug Breakouts: What is Kymera Therapeutics Incs 5 year growth outlookPortfolio Return Report & Consistent Return Strategy Ideas - baoquankhu1.vn
Weekly Earnings: Is Kymera Therapeutics Inc currently under institutional pressure2026 Price Momentum & Smart Investment Allocation Insights - baoquankhu1.vn
HighVista Strategies LLC Makes New $890,000 Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Holocene Advisors LP Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
KYMR: Jefferies Lowers Price Target but Maintains Buy Rating | KYMR Stock News - GuruFocus
Jefferies Financial Group Initiates Coverage on Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2025 earnings call transcript - MSN
Boxer Capital Management LLC Lowers Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Checkpoint Capital L.P. - MarketBeat
Braidwell LP Takes $15.66 Million Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside - Yahoo Finance
Kymera Therapeutics, Inc. $KYMR Stock Position Lessened by Avoro Capital Advisors LLC - MarketBeat
Can Kymera Therapeutics’ (KYMR) Oral Degraders Redefine Its Long-Term Edge Over Biologic Rivals? - simplywall.st
Kymera at Barclays Conference: Strategic Focus on Immunology By Investing.com - Investing.com Canada
KYMR: Advancing oral immunology therapies with robust pipeline and strong financial runway - TradingView
Kymera Therapeutics CFO presents new immunology strategy at Barclays Healthcare Conference - Traders Union
Morgan Stanley maintains Kymera Therapeutics (KYMR) overweight recommendation - MSN
Kymera Therapeutics, Inc. $KYMR Holdings Trimmed by Atika Capital Management LLC - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 25,758 Shares - MarketBeat
Kymera Therapeutics COO Sells Shares Worth Over $2 Million - TradingView
Kymera (NASDAQ: KYMR) COO exercises 20,000 options and sells 25,758 shares - Stock Titan
Jeremy Chadwick reports KYMR transactions (NASDAQ: KYMR) including 20,000-option line - Stock Titan
Hedge Fund Moves: Can Kymera Therapeutics Inc weather a recessionVolume Spike & Daily Chart Pattern Signals - baoquankhu1.vn
Kymera to present atopic dermatitis trial data at AAD meeting By Investing.com - Investing.com Canada
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Clinical Trial of KT-621 - MSN
Kymera at Leerink Global Healthcare: Strategic Insights on Drug Development By Investing.com - Investing.com Canada
KYMR: KT-621 shows strong early efficacy and safety; pivotal Phase 2b readouts expected in 2027 - TradingView
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology Annual Meeting - Investing News Network
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting - Bitget
Experimental atopic dermatitis pill KT-621 heads to late-breaking AAD stage - Stock Titan
Kymera CEO Nello Mainolfi’s Boldest Line Had Nothing to Do With the Earnings Miss - Yahoo Finance
Market Moves: What is the long term forecast for Kymera Therapeutics Inc. stockWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
Kymera Therapeutics Inc (KYMR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):